SCHEDULE 13G/A: BlackRock Discloses 17.4% Stake in Lemaitre Vascular Inc.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a significant beneficial ownership of 17.4% in Lemaitre Vascular Inc. as of December 31, 2024.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,913,433 shares of Common Stock in Lemaitre Vascular Inc.
• This ownership represents 17.4% of the total outstanding common stock of Lemaitre Vascular Inc.
• BlackRock holds sole voting power over 3,764,756 shares and sole dispositive power over 3,913,433 shares.
• No shared voting or dispositive power was reported.
• The filing was made pursuant to Rule 13d-1(b), indicating BlackRock is an institutional investor holding shares in the ordinary course of business, not for control purposes.
• One of BlackRock's entities, iShares Core S & P Small-Cap ETF, holds more than 5% of the total outstanding common stock of Lemaitre Vascular Inc.
• BlackRock Fund Advisors, another BlackRock entity, also beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant 17.4% stake by a major institutional investor like BlackRock is generally viewed positively, indicating confidence in the company's long-term prospects, even though it's a passive investment.

Positives

• BlackRock's significant 17.4% stake indicates strong institutional confidence in Lemaitre Vascular Inc.
• The filing confirms BlackRock's position as a major long-term investor, holding shares in the ordinary course of business.

Risks

• The document does not detail specific risks related to Lemaitre Vascular Inc.'s operations or financial performance, as it is a beneficial ownership report.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Lemaitre Vascular Inc.'s future performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from BlackRock, Inc.)

Industry Context

This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., indicating its passive investment stake in Lemaitre Vascular Inc., a company operating in the medical technology and vascular devices sector. Such disclosures provide transparency into significant institutional holdings, which can signal investor confidence or interest in a particular industry or company.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports beneficial ownership and does not provide financial or operational results for comparison to industry standards.
• The 17.4% stake held by BlackRock is a substantial institutional holding, often seen in companies within the small to mid-cap range, indicating significant conviction from a major asset manager.
• While specific comparable companies or projects are not mentioned in the filing, BlackRock's investment in Lemaitre Vascular Inc. suggests its inclusion in portfolios alongside other medical technology firms that meet BlackRock's investment criteria.

Stakeholder Impact

• Shareholders: The disclosure of a large institutional stake by BlackRock may increase investor confidence and potentially influence trading activity.
• Management: Awareness of a significant institutional shareholder like BlackRock may influence strategic decisions, though BlackRock states its holding is for passive investment purposes.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G if there are material changes to its beneficial ownership of Lemaitre Vascular Inc. shares.

Key Dates

Keywords

Lemaitre Vascular Inc., BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Vascular Devices, Medical Technology, Investment Management, Shareholding